Literature DB >> 8728608

Role of verotoxin receptors in pathogenesis.

C A Lingwood1.   

Abstract

Verotoxin-globotriaosyl ceramide (Gb3) binding is the linchpin in disease induced by verotoxin-producing Escherichia coli (VTEC), and defines cell sensitivity, tissue tropism, mode of systemic transport, specific cytotoxic activity and internal routing within sensitive cells. Binding explains the epidemiology of renal pathology, which may follow VTEC infection. Lipid heterogeneity of Gb3 is important in binding, and may define a growth-related signal transduction pathway used by verotoxin.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8728608     DOI： 10.1016/0966-842x(96)10017-2

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN： 0966-842X            Impact factor:   17.079


  91 in total

1.  Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication.

Authors:  Abhineet S Sheoran; Igor P Dmitriev; Elena A Kashentseva; Ocean Cohen; Jean Mukherjee; Michelle Debatis; Jonathan Shearer; Jacqueline M Tremblay; Gillian Beamer; David T Curiel; Charles B Shoemaker; Saul Tzipori
Journal:  Infect Immun       Date:  2014-11-03       Impact factor: 3.441

2.  Shiga toxin 1 from Escherichia coli blocks activation and proliferation of bovine lymphocyte subpopulations in vitro.

Authors:  C Menge; L H Wieler; T Schlapp; G Baljer
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

3.  A novel sphingophosphonolipid head group 1-hydroxy-2-aminoethyl phosphonate in Bdellovibrio stolpii.

Authors:  Y Watanabe; M Nakajima; T Hoshino; K Jayasimhulu; E E Brooks; E S Kaneshiro
Journal:  Lipids       Date:  2001-05       Impact factor: 1.880

4.  Cloning a truncated fragment (stx2a(1)) of the shiga-like toxin 2A (1) subunit of EHEC O157:H7: candidate immunogen for a subunit vaccine.

Authors:  Lu Liu; Hao Zeng; Ping Luo; Jian Wu; Hongzhang Chen; Yun Shi; Weijun Zhang; Xuhu Mao; Bin Xiao; Quanming Zou
Journal:  Mol Biotechnol       Date:  2009-05-12       Impact factor: 2.695

Review 5.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.

Authors:  Carlamaria Zoja; Simona Buelli; Marina Morigi
Journal:  Pediatr Nephrol       Date:  2017-12-06       Impact factor: 3.714

6.  A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model.

Authors:  Leticia V Bentancor; Marcos Bilen; Romina J Fernández Brando; María Victoria Ramos; Luis C S Ferreira; Pablo D Ghiringhelli; Marina S Palermo
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

Review 7.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

8.  The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein.

Authors:  A Puri; P Hug; K Jernigan; J Barchi; H Y Kim; J Hamilton; J Wiels; G J Murray; R O Brady; R Blumenthal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

9.  Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells.

Authors:  Ivan U Kouzel; Gottfried Pohlentz; Wiebke Storck; Lena Radamm; Petra Hoffmann; Martina Bielaszewska; Andreas Bauwens; Christoph Cichon; M Alexander Schmidt; Michael Mormann; Helge Karch; Johannes Müthing
Journal:  J Lipid Res       Date:  2012-12-17       Impact factor: 5.922

10.  Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.

Authors:  Greice Krautz-Peterson; Susan Chapman-Bonofiglio; Karen Boisvert; Hanping Feng; Ira M Herman; Saul Tzipori; Abhineet S Sheoran
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.